Pharnext is a biopharmaceutical company co-founded in 2007 by Truffle Capital. The company is developing new treatments targeting severe neurodegenerative diseases - rare or common - currently without a satisfactory therapeutic solution.
See website
Synoptical view
- Truffle investment
- € 15M
- Stock
- Pharnext is listed on EURONEXT GROWTH PARIS since 2016
Management team
Board of Directors
As a former Paris hospital intern in immunology and hematology, Dr Pouletty holds a doctorate in medicine from the University of Paris VI and a master's degree in immunology and virology from the Institut Pasteur. He was a post-doctoral researcher (1986-1988) at Stanford University.
He is the winner of the 1999 American Liver Foundation Award. Doctor Philippe Pouletty is a Chevalier de la Légion d'Honneur.
">
Philippe Pouletty, M.D.
Co-Founder & CEO at Truffle Capital
In summary
Pharnext has two flagship products in clinical development, one for the treatment of Charcot-Marie-Tooth disease type 1A, the other for the treatment of Alzeimer's disease. Pharnext has developed a new paradigm for drug discovery based on large genomic data and artificial intelligence: PLEOTHERAPY. The company identifies and develops synergistic drug combinations
KEY STEPS
2009
Alzheimer's PXT-864: phase 1 completed
2016
Finalization of the IPO
2018
LEODRUGGTM PXT 3003 obtains priority evaluation of Charcot-Marie-Tooth disease type 1a by the China Food and Drug Administration. Pharnext announces positive results from the pivotal Phase 3 trial of PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A
News
